YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., July 14, 2015 /PRNewswire/ -- ReWalk Robotics Ltd. (Nasdaq: RWLK), the leading global exoskeleton manufacturer, unveiled today the latest edition of its Personal powered exoskeleton system—the ReWalk Personal 6.0—marking the company's sixth generation community use product. The ReWalk Personal 6.0 offers those in the spinal cord injured community the most functional exoskeleton system with the fastest walking speed and the most precise fit, among many other key benefits. The ReWalk Personal 6.0 is the latest version of the FDA cleared exoskeleton, which can be used at home and in the community.
"The launch of the 6.0 offers those with spinal cord injury an exoskeleton design that fits better, walks faster and has better gait control than prior generations of the product," said ReWalk's CEO Larry Jasinski. "Our design efforts are built on many years of user experience with a philosophy of offering an outstanding product for use in all aspects of everyday life. The enhanced design of the 6.0 offers highly customized fittings, and software to better match the size and anatomy of each individual user, providing a better walking experience than any prior design and over any other known products in clinical trials around the world."
The ReWalk 6.0 System at a Glance:
The Most Precise Fit: The Personal 6.0 System is fitted to the user's measurements and custom ordered for each individual. This precise fit enhances system function, safety and alignment of the user's joints.
Fastest Walking Speed: Clinical research on the ReWalk device has demonstrated that users can walk at speeds up to 0.71 meters / second, faster than any other exoskeleton.
Streamlined Design: The removal of the backpack eliminates weight from the shoulders, giving the user freedom for clothing choice and movement. The sleek redesign of the strapping and padding provides the users with an easier and faster capacity to put the system on and take it off.
"Our experience and feedback from daily use of the ReWalk systems in the community, combined with technical advances achieved by our R&D organization have enabled this next generation prosthetic exoskeleton," said Jodi Gricci, VP of Global Marketing and Training at ReWalk. "Our user evaluations with the 6.0 demonstrated the value of better fit, improved gait control and more comfort with the removal of the backpack in this streamlined design."
ReWalk remains the only exoskeleton manufacturer in the United States with FDA clearances for both its Personal and Rehabilitation systems. ReWalk has also received regulatory clearances for their systems in several global geographies including: North America, Europe, Asia, the Middle East and Australia. ReWalk is the most used exoskeleton worldwide, with Personal and Rehabilitation Systems in use across several continents.
ReWalk is the most studied exoskeleton in the industry. The wealth of clinical data has provided great insight into the potential health benefits that result from standing and walking using the ReWalk systems. Studies have identified a number of health benefits including: improved bladder and bowel function, improved mental health, improved sleep, reduced fatigue, decreased body fat, decreased pain and improved posture and balance.
The ReWalk Personal 6.0 Systems are now available for purchase, with anticipated delivery of the first units this summer.
Members of the media: ReWalk CEO Larry Jasinski will be available for interview in New York City July 14 and 15. In addition there will be ReWalkers available for interview and demonstration of the 6.0 system. All Media Inquiries: Jennifer Wlach, 202-551-1454 // email@example.com
For cleared photos of the ReWalk 6.0 Personal System: http://bit.ly/1HYLvmS
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk's future performance and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and to expand to new markets; ReWalk's ability to maintain and grow its reputation and the market acceptance of our products; ReWalk's ability to achieve reimbursement from third-party payors for our products; ReWalk's expectations as to its clinical research program and clinical results; ReWalk's ability to improve its products and develop new products; ReWalk's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk's ability to gain and maintain regulatory approvals; ReWalk's ability to maintain relationships with existing customers and develop relationships with new customers; and other factors discussed under the heading "Risk Factors" in the U.S. Annual Report on the Form 20-F for the year ended December 31, 2014 filed with the U.S. Securities and Exchange Commission on February 27, 2015 and other documents filed with or furnished to the U.S. Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. ReWalk's mission is to fundamentally change the health and life experiences of individuals with spinal cord injury. Founded in 2001, ReWalk has headquarters in the US, Israel and Germany. For more information on the ReWalk systems, please visit http://www.rewalk.com.
ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel.
SOURCE ReWalk Robotics